#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to recognize that modern cannabis products contain significantly higher THC concentrations than historical products, increasing the risk of adolescent cannabis use disorder and requiring updated screening and counseling protocols in pediatric practice. Early identification and intervention for cannabis addiction in young patients is critical, as developing brains are more vulnerable to addiction and cognitive effects from high-potency products. This emerging trend suggests clinicians should proactively discuss cannabis potency and addiction risks with teen and preteen patients during routine visits, particularly given the perception that cannabis is harmless compared to other substances.
A pediatric hospital system is reporting increased cases of cannabis use disorder in adolescents, with clinicians attributing the rise primarily to dramatically elevated THC potency in modern cannabis products compared to historical levels. Whereas traditional marijuana plants contained 1 to 5 percent THC, contemporary products including concentrates and edibles now contain substantially higher concentrations, increasing the risk of dependence and problematic use patterns in developing brains. This trend is clinically significant because adolescent cannabis use, particularly of high-potency products, is associated with cognitive impacts, mental health complications, and potential gateway effects to other substance use. Pediatricians and family medicine clinicians should be aware that today’s cannabis products pose a meaningfully different risk profile than what patients’ own prior experience or outdated public perception may suggest. Clinicians caring for teenagers should screen routinely for cannabis use, counsel on the specific risks of high-potency products, and recognize cannabis use disorder as an emerging adolescent health concern requiring evidence-based intervention.
“What we’re seeing clinically is that adolescent cannabis use disorder has become a genuine public health concern, driven largely by products that are 10 to 20 times more potent than what previous generations encountered, and parents need to understand this isn’t the same substance their kids are accessing that they may have tried decades ago.”
🧠 The rising prevalence of cannabis use disorder in pediatric populations warrants clinical attention, particularly given the dramatically increased potency of modern cannabis products, which can now contain 20-40% THC compared to historical averages of 1-5%. Clinicians should recognize that adolescent brain development, ongoing through the mid-twenties, may confer particular vulnerability to dependence and cognitive effects with high-potency exposure. Important confounders include the role of product formulation (edibles, concentrates, and vaping delivery systems may have different pharmacokinetics and abuse potential), concurrent mental health conditions that often drive cannabis initiation, and variable legal and social access across jurisdictions. While more longitudinal research is needed on causality and dose-response relationships in youth, the clinical implication is clear: pediatric and adolescent providers should routinely screen for cannabis use with non-judgmental questioning, counsel families about potency risks during
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: